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MorphogenesisStrong evidences support the inhibitory activity of cellular FLICE-inhibitory protein (FLIP) in the apoptotic
signalling by death receptors in tumor cells. However, little is known about the role of FLIP in the regulation of
apoptosis in non-transformed cells. In this report, we demonstrate that FLIPL plays an important role as a
survival protein in non-transformed breast epithelial cells. Silencing of FLIPL by siRNA methodology enhances
TRAIL-R2 expression and activates a caspase-dependent cell death process in breast epithelial cells. This cell
death requires the expression of TRAIL, TRAIL-R2, FADD and procaspase-8 proteins. A mitochondria-operated
apoptotic pathway is partially required for FLIPL siRNA-induced apoptosis. Interestingly, FLIPL silencing
markedly abrogates formation of acinus-like structures in a three-dimensional basement membrane culture
model (3D) of the human mammary MCF-10A cell line through a caspase-8 dependent process. Furthermore,
over-expression of FLIPL in MCF-10A cells delayed lumen formation in 3D cultures. Our results highlight the
central role of FLIP in maintaining breast epithelial cell viability and suggest that the mechanisms regulating
FLIP levels should be ﬁnely controlled to prevent unwanted cell demise.poptosis-inducing ligand; TNF,
omplex; FADD, Fas-associated
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Apoptosis is a highly regulated cell death process that is required
for integrity and homeostasis of multicellular organisms and is also
important in embryonic development [1]. Deregulation of apoptosis
contributes to different pathological states [2,3]. Moreover, defects in
the apoptosis machinery can result in drug resistance by tumor cells
[4]. The past decade has witnessed an enormous progress in our
knowledge of the pathway for the execution of apoptotic cell death
and both mitochondria-dependent and -independent mechanisms
have been involved in the induction of apoptosis by different
treatments [5]. By exploiting this knowledge base, a number of
innovative strategies for treating cancer have been implemented [4].
In contrast tomany therapeutic drugs that induces apoptosis by acting
at the mitochondrial level, the so-called extrinsic pathway of
apoptosis utilises membrane-localized “death receptors” to activate
the caspase cascade and apoptosis upon ligand binding. These
receptors are members of tumor necrosis factor (TNF) receptor
superfamily [6]. Amongst their ligands, TRAIL (APO-2 ligand), amember of the TNF family, is a type II transmembrane protein with
important functions as an apoptosis inducer in the immune system
[7]. Moreover, TRAIL selectively induces apoptosis inmany tumor cells
while leaving normal cells intact and thus is an attractive candidate
for antitumor therapies [8], although resistance to TRAIL has been
reported in certain tumor cells [9,10].
Activation of TRAIL receptors leads to the formation of a death-
inducing signalling complex (DISC), which includes the receptor itself,
the adapter molecule FADD and procaspase-8 [11,12]. Processing and
activation of caspase-8 at the DISC lead to a cascade of apoptotic
events which results in the death of the cell. At the DISC level, the
apoptotic signal may be inhibited by FLIP, the homologue of vFLIP in
vertebrate cells [13]. In most cells, cellular FLIP exists as two
alternative spliced isoforms: FLIPL, a homologue of caspase-8, which
lacks critical amino acids for proteolytic caspase activity, and FLIPS,
consisting only of two death effector domains (DED) [13]. A third
23 kDa recently identiﬁed form, called FLIPR with properties similar to
those of FLIPS is also expressed in some cells [14]. FLIP expression
ﬂuctuates in a cell-type-speciﬁc manner and in response to various
stimuli, transcriptionally through the NF-κB pathway [15], and at the
protein level via altered rates of proteasomal degradation [16], which
makes it a versatile inhibitor of apoptotic responses mediated by
death receptors. Accumulating evidence indicates an anti-apoptotic
function for FLIPL in many types of human cancer cells [17,18],
although it could also play a pro-apoptotic role under certain
conditions [19]. In normal cells, FLIP has been shown to exert other
functions related to cell activation and proliferation [20–24]. In this
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development independently of its antiapoptotic function [25].
However, little is known about the role of FLIP as a survival factor
and regulator of apoptosis in normal cells. In this study, we examined
the importance of FLIP as a survival factor for normal breast epithelial
cells in conventional cultures of cells in monolayers as well as in
three-dimensional (3D) cultures that better resemble the in vivo
architecture of a glandular epithelium [26]. We show that knockdown
of FLIPL in normal breast epithelial cells by RNA interference induces
spontaneous apoptosis through a ligand-dependent TRAIL receptor-
mediated pathway. We also demonstrate that in 3D cultures, FLIPL
regulates the formation of acini-like structures.
2. Material and methods
2.1. Reagents and antibodies
EGF was from PeproTech (London, UK). Insulin and puromycin
were purchased from Sigma Chemical Corp. Soluble human His-
tagged recombinant TRAIL (residues 95–281) was produced as
described [27]. Anti-FLIP monoclonal antibody (NF6) was from Alexis
Corp. (San Diego, CA). Anti-caspase 8 was generously provided by Dr.
Gerald Cohen (Leicester University, UK). Antibody anti-FADD and
growth factor reduced Matrigel were obtained from BD Bioscience
(Erembodegem, Belgium). Monoclonal antibodies to alpha-tubulin
and vimentin were purchased from Sigma Chemical Corp. Antibodies
anti-GAPDH and anti-CD95/Fas were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Anti-Bidwas generously provided by Dr. XWang
(Howard Hughes Institute, Dallas, Texas). Antibodies against TRAIL-
R1/DR4, TRAIL-R2/DR5 and TRAIL were from R&D Systems (Minnea-
polis, USA). Anti-cleaved caspase-3 was from Cell Signalling (MA,
USA). Anti-Ki67 was from Zymed (Invitrogen Ltd., Paisley, UK). Anti-
Bcl2 and horseradish peroxidase conjugated secondary antibodies
were obtained from DAKO (Cambridge, United Kingdom). Benzylox-
ycarbonyl-Val-Ala-Asp-(OMe) ﬂuoromethyl ketone (zVAD-fmk) was
purchased from Bachem AG (Bachem, Bubendorf, Switzerland).
Subcellular Proteome Extraction kit was from Calbiochem (Merck
Chemicals, Darmstadt, Germany).
2.2. Cell lines
Cell lines were either maintained in RPMI medium (MDA-MB231)
or in DMEM medium (HEK293-T and BT-474) containing 10% fetal
bovine serum, 2 mM glutamine, 50 U of penicillin/ml, and 50 μg of
streptomycin/ml. MCF-10A cells were maintained in DMEM/F12
supplemented with 5% donor horse serum, 2 mM L-glutamine, 20 ng
of epidermal growth factor (EGF)/ml, 10 μg of insulin/ml, 100 ng of
cholera toxin/ml, 0.5 μg of hydrocortisone/ml, 50 U of penicillin/ml,
and 50 μg of streptomycin/ml. All cell lines were maintained at 37 °C
in a humidiﬁed 5% CO2, 95% air incubator.
2.3. siRNA
siRNA against FLIP (5′-GGGACCUUCUGGAUAUUUUdTdT-3′), FLIPL
(5′-GAGCAUACCUGAAGAGAGAdTdT-3′, 5′CAUGGUAUAUCCCA-
GAUUCdTdT, 5′CCUAGGAAUCUGCCUGAUAdTdT), FLIPS (5′-CACC-
CUAUGCCCAUUGUCCdTdT-3′), Caspase-8 (5′-GGAGCUGCUC
UUCCGAAUUdTdT-3′), FADD (5′-GAAAGACCUGUGUGCAGCAUdTdT-
3′), TRAIL-R1/DR4 (5′-CACCAAUGCUUCCAACAAUdTdT-3′), TRAIL-R2/
DR5 (5′-GACCCUUGUGCUCGUUGUCdTdT-3′), CD95/FAS (5′-AAGCC-
CUGUCCUCCAGGUGAAdTdT-3′), Bid (5′-GAAGACAUCAUCCG-
GAAUAdTdT-3′) and Scrambled (5′-GAGCGCUAGACAAUGAAGdTdT-
3′) were from SIGMA-Proligo (Boulder, CO). siRNA against TRAIL
(FlexiTube siRNA, 5′-GGUCCAAUAUAUUUACAAAdTdT-3′) was from
Quiagen (Crawley, UK). Cells were transfected with siRNAs usingDharmaFECT 1 (Dharmacon, Lafayette, CO) as described by the
manufacturer.
2.4. Retroviral and lentiviral vectors and virus production
FLIPL (in pCR3.V64 vector, a kind donation of Dr. J. Tschopp,
University of Lausanne) was cloned into BamHI/SalI sites of pBabe-
puro. pBabe-dnFADD and pBabe-Bcl2 vectors have been previously
described [28]. Retroviruses for protein over-expression were
produced by transfection of HEK293-T cells with the corresponding
retroviral vectors. Retrovirus-containing supernatants were collected
at days 5–7 after transfection and were stored at −80 °C. shRNA
against FLIPL (5′-GAGCATACCTGAAGAGAGA-3′) or scrambled (5′-
TATAGTCCGCGTTTTGTGA-3′) in a pSUPER vector (OligoEngine) was
digested and cloned between EcoR1 and Cla1 into a H1 promoter-
driven GFP-encoding pLVTHM lentiviral vector [29]. Lentiviruseswere
produced by transient cotransfection of HEK293-T cells with the
corresponding lentiviral vector, packaging plasmid psPAX2 and
envelope plasmid pMD2.G. Lentivirus-containing supernatants were
collected at day 3 after transfection by centrifugation.
2.5. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was isolated from cells with Trizol reagent (Life
Technologies, Inc.) as recommended by the supplier. cDNAs were
synthesized from 2 μg of total RNA using a RT-PCR kit (PerkinElmer
Life Sciences) with the supplied oligo(dT) primer under conditions
described by the manufacturer. PCR reactions were performed using
the following primers: TRAIL-R2 sense, 5′-GCCTCATGGACAATGAGA-
TAAAGGTGGCT-3′; TRAIL-R2 antisense, 5′-CCAAATCTCAAAGTACGCA-
CAAACGG-3′.
2.6. Generation of MCF-10A cell lines
MCF-10A cells were plated at 5×105 cells per 10-cm dish and
infected with the retroviruses mentioned above. Stable populations
were obtained by selection with 2 μg/ml puromycin. MCF-10A cells
were plated at 8×104 cells per 35-mm dish and infected with the
lentiviruses during 48 h. Then the cells were used for 3D morpho-
genesis assays.
2.7. Morphogenesis assay
Assays were performed as previously described [30,31]. Brieﬂy,
MCF-10A cells were resuspended in assay medium (DMEM/F12
supplemented with 2% donor horse serum, 10 μg of insulin/ml,
100 ng of cholera toxin/ml, 0.5 μg of hydrocortisone/ml, and 5 ng of
EGF/ml). Eight-well RS glass slides (BD Falcon) were coated with 40 μl
of Matrigel per well. Then, 5×103 cells were plated per well in assay
medium containing a ﬁnal concentration of 2% Matrigel. Assay
medium containing 2% Matrigel was replaced every 4 days.
2.8. Immunoﬂuorescence and image acquisition
Structures were prepared as previously described [30,31]. Brieﬂy,
acini were ﬁxed in 4% formalin for 25 min at room temperature. Fixed
structures were washed with PBS-glycine (130 mM NaCl, 7 mM
Na2HPO4, 100 mM glycine) three times for 15 min each time. The
structures were then blocked in IF buffer (130 mM NaCl, 7 mM
Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% bovine serum
albumin, 0.2% Triton X-100, 0.05% Tween-20) plus 10% goat serum
for 1 to 2 h, followed by 2% blocking buffer (i.e., IF buffer containing
10% goat serum and 20 μg of goat anti-mouse F(ab)2/ml) for 40 min.
Primary antibodies were diluted in 2% blocking buffer, followed by
incubation overnight at 4 °C. Structures were washed three times in IF
buffer for 15 min each. Anti-mouse or anti-rabbit secondary
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diluted in IF buffer containing 10% goat serum, followed by incubation
for 60 min. After a wash with IF buffer as described above, structures
were incubated with 0.5 ng of DAPI (4-6-diamidino-2-phenylindole;
Sigma)/ml before being mounted with the antifade agent Prolong
Gold (Molecular Probes). Confocal analysis was performed in a Leica
TCS-SP5 laser microscope.
For the analysis of caspase-3 activation and cell proliferation in 3D
cultures, MCF-10A cells were infected with GFP-encoding lentiviral
vectors for 48 h and harvested for 3Dmorphogenesis assay. Cells were
cultured for 5 days in Matrigel and then the percentage of GFP-
positive acini was assessed by confocal microscopy. Active caspase-3
and Ki67 immunoﬂuorescence were determined in GFP-positive acini.
2.9. Analysis of apoptosis
Hypodiploid apoptotic cells were detected by ﬂow cytometry
according to published procedures [32].
2.10. Immunoblot analysis of proteins
Proteins were resolved on SDS-polyacrylamide minigels and
detected as described previously [33].
2.11. Analysis of cell surface proteins by ﬂow cytometry
Cells were detached from the culture dish with RPMI 1640
medium containing 3 mM EDTA and cytoﬂuorimetric analysis of
proteins was performed as described [34]. The following antibodies
were used in these studies: anti-TRAIL-R1, anti-TRAIL-R2 and anti-
CD95/Fas (DX2) from Abcam (Cambridge, UK), PE or FITC-conjugated
afﬁnity-puriﬁed rabbit anti-mouse immunoglobulins from DAKO
(Glostrup, Denmark), PE-labelled mouse anti human CD253 (TRAIL)
and mouse IgG1 k isotype control from BD Biosciences (Erembode-
gem, Belgium).
2.12. Statistical analysis
Data are presented as mean±S.E.M. of duplicate samples from at
least three independent experiments. Differences between treatment
groups were determined by using the Mann-Whitney test. Statistical
signiﬁcancewas evaluated by calculating P values. P values below 0.05
were considered signiﬁcant.
3. Results
3.1. Dual role of FLIP as inhibitor of TRAIL-induced apoptosis and
survival protein in breast epithelial cells
Recent results from our laboratory have demonstrated the
existence of intracellular mechanisms of resistance to TRAIL-induced
apoptosis in a variety of breast tumor cell lines. Our data indicated
that treatments like IFN gamma, glucose deprivation and inhibitors of
cyclin-dependent kinases sensitize breast tumor cells to TRAIL-
induced apoptosis [35–37]. This sensitization process involves the
increased formation of the death-inducing signalling complex (DISC),
mediated by regulating the expression of DISC proteins. To under-
stand the mechanism underlying the resistance of breast tumor cells
to TRAIL we determined the role of FLIP isoforms by siRNA
methodology. Results shown in Fig. 1 demonstrate that simultaneous
silencing of both FLIPL and FLIPS isoforms resulted in an increased
sensitivity to TRAIL-induced apoptosis in the cell lines studied. In
these experiments we observed that simultaneous knockdown of
both c-FLIP isoforms resulted in spontaneous cell death as previously
reported in other tumor cell lines [18,38,39]. We next examined the
role of individual FLIP isoforms in the sensitivity of breast tumor cellsto TRAIL. In BT474 cells, knockdown of FLIPL was sufﬁcient to
markedly sensitize these cells to TRAIL-induced apoptosis. In contrast,
silencing of FLIPL expression did not sensitize MDA-MB231 cells to
TRAIL. A likely explanation for these results may be the different levels
of FLIPS isoform between these two cell lines (Fig. 1), with MDA-
MB231 cells expressing higher levels of FLIPS than BT-474 cells. On the
other hand, FLIPS knockdown did not induce sensitivity to TRAIL in
any of the cell lines tested, all of them expressing elevated levels of
FLIPL isoform. These results suggest that FLIPL levels are important
determinants of the sensitivity of breast tumor cells to TRAIL-induced
apoptosis.
We also examined the role of FLIP isoforms in the sensitivity of
non-transformed breast epithelial cells to TRAIL-induced apoptosis.
Silencing the expression of either isoform in MCF-10A cells markedly
sensitized these cells to TRAIL-induced apoptosis (Fig. 2a). Interest-
ingly, we observed that knockdown of FLIPL caused spontaneous
apoptosis in the absence of exogenously added TRAIL. Similar results
were obtainedwith two different siRNAs to FLIPL (Fig. 2b). In contrast,
silencing FLIPS expression by siRNA did not induce apoptosis in MCF-
10A cells (Fig. 2a). Moreover, over-expression of FLIPL with a
retroviral vector clearly inhibited spontaneous apoptosis in MCF-
10A cells (Fig. 2c), further indicating that apoptosis induced upon
FLIPL knockdown by siRNA is not due to off-target effects of the
siRNAs.3.2. Activation of TRAIL-R2-mediated apoptosis in non-transformed
breast epithelial cells by FLIPL knockdown
We then studied the mechanism of apoptosis induced by FLIPL
knockdown in non-transformed cells. Spontaneous apoptosis follow-
ing FLIPL knockdown was completely inhibited by the pan-caspase
inhibitor z-VAD-fmk (Fig. 3a), demonstrating the participation of
caspases in this cell death process. Furthermore, silencing of FLIPL
resulted in the activation of caspase-8, -9 and -3 and the cleavage of
the caspase substrate PARP in MCF-10A cells (Fig. 3b). We next
determined the requirements for the activation of apoptosis by FLIPL
siRNA in MCF-10A cells and whether the extrinsic pathway was
involved in this process. MCF-10A cells mainly express TRAIL-R2/DR5
and this receptor is responsible for the apoptosis observed in
sensitized cells treated with TRAIL [40]. To ﬁnd out whether the
apoptosis induced by FLIPL knockdown requires the expression of
TRAIL-R2/DR5, MCF-10A cells were incubated with siRNAs to TRAIL-
R2/DR5 and FLIPL and apoptosis was then measured. Results shown in
Fig. 4a indicate that silencing TRAL-R2/DR5 expression completely
abrogated spontaneous apoptosis caused by FLIPL knockdown. In
these experiments we observed that silencing FLIPL enhanced TRAIL-
R2 expression at the protein level (Fig. 4a and Supplementary Fig. 1a,
b). In contrast, TRAIL-R1 levels were not affected by FLIPL knockdown
(Supplementary Fig. 1b). Ligand-independent assembly of the DISC
has been demonstrated in the TNF family of death receptors [41], most
likely due to the homotypic association of receptors mediated by the
pre-ligand-binding assembly domain (PLAD) [42]. Furthermore,
increased TRAIL-R2/DR5 expression by gene transfection has been
previously demonstrated to be sufﬁcient to induce apoptosis in the
absence of ligand [43]. However, cell surface levels of TRAIL-R2 did not
change in FLIPL-depleted cells (Supplementary Fig. 1c). Whether the
increase in TRAIL-R2 levels upon FLIPL knockdown is involved in the
activation of the apoptotic process is an issue that requires further
investigation. As it has been reported that TRAIL-R2 can form
heteromeric complexes with TRAIL-R1 [11] we also examined the
role of TRAIL-R1 in apoptosis induced upon FLIPL knockdown. A partial
inhibition of apoptosis by siRNA to FLIPL was observed in MCF-10A
depleted of TRAIL-R1 (Fig. 4a). These results suggest that a certain
amount of heteromeric complexes TRAIL-R1/R2 may be involved in
the induction of apoptosis by FLIPL siRNA.
Fig. 1. Knockdown of endogenous FLIP sensitizes breast tumor cells to TRAIL-induced cell death. a) MDA-MB231 and b) BT474 cells were transfected with siRNA oligonucleotides
targeting both FLIP isoforms (FLIP), FLIP long (FLIPL) or FLIP short (FLIPS) as described in Material and methods. A scrambled RNA was also used as non-targeting control
oligonucleotide. After 24 h cells were treated with TRAIL 50 ng/ml (MDA-MB231) or 500 ng/ml (BT474) for 24 h. Apoptosis was measured as percentage of cells with sub-G1 DNA
content. Results show the average and S.E.M. of duplicates from three different experiments. **Pb0.01, *Pb0.05. We also veriﬁed protein knockdown by immunoblot analysis. Cells
were harvested prior to the addition of soluble recombinant TRAIL. Tubulin was used as a protein loading control.
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FLIP siRNA has been described in colorectal cancer cell lines [18]. We
also determined the role of CD95/Fas in the activation of apoptosis
upon FLIPL knockdown in untransformed MCF-10A cells. Results
shown in Supplementary Fig. 2 demonstrates that although FLIPL
silencing enhanced CD95/Fas expression as determined by western
blotting, no changes were detected when the cell surface expression
was analyzed. As for TRAIL-R2 we examined the role of CD95/Fas in
the apoptosis induced by FLIPL siRNA. In contrast to the complete
inhibition of apoptosis elicited by depleting the cells of TRAIL-R2,
CD95/Fas knockdown only slightly reduced the induction of apoptosis
by FLIPL siRNA (Supplementary Fig. 2c).
Activation of the extrinsic pathway upon engagement of the pro-
apoptotic TRAIL receptors by TRAIL requires the formation of a death-
inducing signalling complex (DISC), which includes the receptor itself,
the adapter molecule FADD and procaspase-8 [11,12]. To determine
the role of FADD in the apoptosis induced by FLIPL silencing in normal
breast epithelial cells, we used two different experimental
approaches. In the ﬁrst place, FADD expression was reduced in
MCF-10A cells by a speciﬁc siRNA (Fig. 4b) and the effect on
spontaneous apoptosis by FLIPL silencing was determined. Results
shown in Fig. 4b indicate that FADD knockdown partially inhibited
apoptosis induced by FLIPL siRNA. Residual FADD present in cells
incubated with FADD siRNA may explain the ﬁnding that only partial
inhibition of apoptosis was observed. To further explore the role of
FADD in spontaneous apoptosis by FLIPL siRNA, we performed some
experiments in MCF-10A cells over-expressing a dominant negative
form of FADD (DN-FADD). Data shown in Fig. 4c demonstrate that DN-
FADD markedly reduced apoptosis induced by silencing FLIPL
expression in non-transformed breast epithelial cells. We then
assessed whether caspase-8 was required for the apoptotic process
induced by FLIPL silencing in MCF-10A cells. To this end, caspase-
8 expression was reduced by RNA interference and apoptosis induced
by FLIPL knockdown was determined (Fig. 4d). Our results demon-
strate that caspase-8 silencing completely abrogated the apoptosis
mediated by FLIPL knockdown in these cells. Taken together, thesedata point out to a role of the TRAIL DISC components in spontaneous
apoptosis induced upon a reduction in FLIPL levels in non-transformed
breast epithelial cells.
TRAIL DISC formation is triggered by binding of trimeric ligand to
speciﬁc death receptors [11,12,44]. We then analyzed whether FLIPL
knockdown induced the expression of TRAIL in MCF-10A cells. TRAIL
protein levels are very low in these cells and we could not detect an
increase in TRAIL protein in cells in which FLIPL has been silenced by
siRNA (Fig. 5a). Furthermore, we determined the expression of TRAIL
in the cell surface of control and FLIPL-depletedMCF-10A cells. Results
shown in Fig. 5b indicate theMCF-10A cells did not express detectable
levels of TRAIL in their plasma membrane and FLIPL silencing did not
induce the expression of TRAIL in the cell surface as determined by
ﬂow cytometry. To exclude a role of secreted TRAIL in the apoptosis
induced by FLIPL knockdown we used a recombinant TRAIL-R2/Fc
chimeric protein that has been shown to potently neutralize the
apoptotic activity of exogenous TRAIL [45]. As shown in Fig. 5c, at
doses ﬁve times higher than those required to inhibit apoptosis by
exogenously added TRAIL, TRAIL-R2/Fc did not inhibit apoptosis
mediated by FLIPL knockdown. To investigate whether endogenous
TRAILmay interact with TRAIL-R2 on route to the cells surface thereby
hindering neutralization by exogenously added TRAILR2-Fc we
performed siRNA experiments to silence TRAIL expression. Interest-
ingly, TRAIL knockdown markedly inhibited the activation of
apoptosis by FLIPL siRNA (Fig. 5d). These results suggest that
endogenous TRAIL may be inducing DISC formation at an intracellular
site that is not affected by exogenous TRAILR2-Fc.
It has been recently demonstrated that TRAIL induces changes in
the subcellular localization of DISC components to achieve full
activation of caspase-8 [46]. To examine the subcellular localization
of the various DISC proteins in MCF-10A cells prior or after TRAIL
addition to the cultures, we used a similar fractionation approach [47].
As previously reported [46], TRAIL induced an increase in the levels of
TRAIL-R2, FADD and caspase-8 in a compartment containing mem-
brane lipid-raft platforms and cytoskeletal proteins. Strikingly, in
MCF-10A cells TRAIL-R2, FADD, procaspase-8 and FLIPL co-localized in
Fig. 2. Knockdown of endogenous FLIPL induces cell death in MCF-10A breast epithelial cells. a) MCF-10A cells were transfected with siRNA oligonucleotides targeting both FLIP
isoforms (FLIP), FLIP long (FLIPL) or FLIP short (FLIPS) for 48 h as described in Material and methods. Then TRAIL (100 ng/ml) was added for a further 24 h period. Apoptosis and
protein knockdown were determined as in Fig. 1. Results show the average and range (apoptosis analysis) or a representative experiment (protein silencing) from two different
experiments. b) MCF-10A cells were transfected with two different siRNA oligonucleotides targeting the long isoform of FLIP, as described in Material and methods. After 72 h
apoptosis wasmeasured as in Fig. 1. Results show the average and range of two different experiments. We also veriﬁed protein knockdown by immunoblot analysis. c) MCF-10A cells
over-expressing FLIPL or control MCF-10A (pBabe) were transfected with siRNA for FLIPL or a scrambled RNA. After 72 h apoptosis was measured as in Fig. 1. Results show the
average and S.E.M. of duplicates from three different experiments. *Pb0.05.
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Fig. 3a). We have also examined the effect of FLIPL siRNA on the
localization of DISC components in MCF-10A cells. Data shown in
Supplementary Fig. 3b indicate that FLIPL knockdown did not affect
the subcellular localization of DISC proteins observed in control cells.
It is possible that the increased expression of TRAIL-R2 observed in
MCF-10A cells following FLIPL silencing (Fig. 4a and Supplementary
Fig. 1a,b) could favour DISC formation and activation by endogenous
TRAIL from this pre-existing co-localization of DISC components.
Ligation of pro-apoptotic TRAIL receptors by their ligand activates
both mitochondria-dependent and independent mechanisms of
apoptosis in various cell types [48,49]. We then asked whether
TRAIL-R2-dependent apoptosis induced by FLIPL silencing required
the activation of a mitochondria-operated pathway. For this purpose,
we silenced the expression of the BH3-only protein Bid, a protein
substrate of caspase-8 involved in the mitochondrial pathwayactivated by death receptors and determined apoptosis in MCF-10A
cells. Results shown in Fig. 6a demonstrate that Bid is at least partially
involved in the apoptosis induced by FLIPL knockdown which
suggested a role of mitochondria in this apoptotic pathway. To further
conﬁrm these results we used MCF-10A cells over-expressing Bcl-2 as
described in Material and methods. Knockdown of FLIPL expression
induced apoptosis in cells infected with an empty retrovirus (Fig. 6b).
In contrast, in cells over-expressing Bcl-2 apoptosis induced by FLIPL
siRNA was partially inhibited, which supports a certain role of the
mitochondria in this apoptotic pathway.
3.3. Role of FLIPL in morphogenesis of acinar structures in 3D cultures of
MCF-10A cells
MCF-10A is a non-transformed human mammary epithelial cell
line which shows many features of normal breast epithelium,
Fig. 3. Caspase activation in cell death induced by FLIPL knockdown. a) MCF-10A cells
were transfected either with a siRNA oligonucleotide targeting the long isoform of FLIP
or a scrambled RNA oligonucleotide, as described in Material and methods. At the same
time, cells were treated with or without z-VAD-fmk (50 μM). After 72 h apoptosis was
measured as in Fig. 1. Results show the average and S.E.M. of duplicates from three
different experiments. **Pb0.01. b) MCF-10A cells were transfected with either a siRNA
oligonucleotide targeting FLIPL or a scrambled oligonucleotide for 32 h. Activation of
caspase-8, caspase-9, caspase-3, PARP cleavage and FLIPL knockdown were assessed by
western blotting. Results are representative of 2 independent experiments. GAPDHwas
used as a protein loading control.
173R. Yerbes et al. / Biochimica et Biophysica Acta 1813 (2011) 168–178including dependence on growth factors and hormones for prolifer-
ation and survival lack of anchorage-independent growth and lack of
tumorigenicity in nude mice [50]. Interestingly, when grown in a
matrix of reconstituted basement membrane components, MCF-10A
cells form acinar structures that retain many characteristics of a
glandular epithelium in vivo [51]. Although it has been reported that
TRAIL may play a role during morphogenesis in vitro [28], nothing is
known about the role of FLIP in the formation of acinar structures in
3D cultures. We then examined whether FLIPL silencing may affect
acini development in MCF-10A cells cultured in matrigel. To stably
silence the expression of FLIPL we generated lentiviral vectors
expressing GFP and either short hairpin RNA (shRNA) against FLIPL
or an irrelevant shRNA. As shown in Fig. 7a, after 48 h in culture FLIP
expression was drastically reduced in viable MCF-10A cells infected
with lentiviral shRNA-FLIPL as compared to a control shRNA. At this
time, viable cells were seeded in matrigel dishes to allow the
formation of acinar structures. Interestingly, after nine days in culture,
the percentage of GFP-expressing acini was markedly reduced in 3D
cultures of MCF-10A infectedwith FLIPL shRNA lentivirus as compared
to cultures of MCF-10A cells infected with control shRNA lentiviral
particles (Fig. 7b). These results indicate that down-regulation of FLIPL
expression impedes the development of acini-like structures and
suggest that FLIPL plays a survival role not only in monolayer cultures
but also in 3D cultures of normal breast epithelial cells by preventing
the onset of an apoptotic cell death process mediated by TRAIL
receptors. Analysis of caspase-3 activation in 3D cultures showed a
high number of acini that were positive for active caspase-3 (80%) inMCF-10A cells infected with FLIPL shRNA lentivirus as compared to
cultures of MCF-10A cells infected with control shRNA lentiviral
particles (20%). In contrast, there were no differences between control
and FLIPL shRNA lentivirus-infected 3D cultures in terms of cell
proliferation (Ki67 staining, not shown). To further examine the role
of FLIPL in the regulation of apoptosis during mammary acini
formation MCF-10A cells were transfected with siRNAs to FLIPL,
caspase-8 or both and the number of acini was assessed after 8 days in
3D cultures. As shown in Fig. 7c, knockdown of caspase-8 prevented
the reduction in acini formation caused by FLIPL siRNA. These results
indicated a role of FLIPL in survival rather than proliferation during
acini formation. When cultured on Matrigel, MCF-10A cells undergo a
series of proliferative and morphogenetic events resulting in the
formation of growth-arrested acini-like spheroids, composed of a
single layer of polarized epithelial cells surrounding a hollow lumen.
In this cell system, lumen formation requires the activation of an
apoptotic process together with the inhibition of proliferation [51]. As
we have demonstrated in this work that FLIPL is a survival factor for
MCF-10A cells and it could also transmit proliferative signals in
certain cell types [20], we asked whether over-expressing it could
have an effect in themorphogenesis of acinar structures in 3D cultures
of MCF-10A cells. Cells were retrovirally transduced to express FLIPL
(Fig. 8a) before culturing then in matrigel containing-medium to
investigate morphogenesis. Luminal clearing was determined after
staining the acini with DAPI and counting the number of intact nuclei
in the lumen. As shown in Fig. 8b and c, FLIPL overexpression in MCF-
10A cells signiﬁcantly delayed lumen formation when compared to
cells infected with a control pBabe retrovirus. Our ﬁndings that
constitutive expression of FLIPL delays luminal clearing in 3D cultures
suggest that the anti-apoptotic properties of this protein may play a
relevant role in the regulation of the morphogenetic process during
acini formation.
4. Discussion
In tumor cells, cellular FLIP is an important modulator of
procaspase-8 activation and thereby controls induction of apoptosis
mediated by death receptors. As an important regulator of caspase-8,
FLIP is responsible for the resistance to death receptor-mediated
apoptosis in many types of tumor cells and has been proposed as a
potential target for therapeutic intervention [52]. At the protein level,
of the three expressed forms of FLIP, FLIPS is clearly an antiapoptotic
molecule with potent activity as inhibitor of caspase-8 at the DISC
[13]. FLIPR has been also reported to inhibit death receptor-induced
apoptosis when overexpressed in cells [14] although its physiological
functions are yet not fully understood. In contrast, the role of FLIPL in
apoptosis regulation has been rather controversial, with studies
indicating an antiapoptotic function [13,39] and others reporting an
allosteric activation of procaspase-8 and enhancement of apoptosis
following death receptor activation [19,53]. Despite these conﬂicting
data, available evidences suggest that FLIPL can either promote or
inhibit death receptor-mediated apoptosis depending on its expres-
sion levels in the cell [54].
Our data indicate that FLIP levels are important determinants of
the resistance of non-transformed breast epithelial cells to TRAIL-
induced apoptosis since a reduction in the cellular levels of FLIP by
RNA interference markedly sensitizes these cells to apoptosis.
Interestingly, our data demonstrate for the ﬁrst time that FLIPL
knockdown in non-transformed breast epithelial cells is sufﬁcient to
induce apoptosis in a TRAIL-R2/DR5-dependent manner. This cell
death mechanism requires endogenous TRAIL and the DISC compo-
nents FADD and procaspase-8 and is partially inhibited by interfering
with the mitochondria-operated apoptotic pathway. In contrast,
silencing FLIPS expression by siRNA did not activate apoptosis in
MCF-10A cells. As FLIPS levels are very low as compared to FLIPL in
these cells, a marked reduction in FLIPL as achieved by siRNA
Fig. 4. Activation of TRAIL receptor-mediated apoptosis by FLIPL knockdown in non-transformed breast epithelial cells. a) MCF-10A cells were transfected with siRNAs for TRAIL-R2
(TR2), TRAIL-R1 (TR1) or both of them for 16 h prior to transfection with siRNA for FLIPL for 30 h. Apoptosis was measured as in Fig. 1. Results show the average and S.E.M. of
duplicates from two different experiments. Immunoblot analysis was performed to verify protein knockdown after FLIPL siRNA transfection. b) MCF-10A cells were transfected with
siRNA for FLIPL or FADD, or both of them at the same time. After 72 h apoptosis was measured as in Fig. 1. Results show the average and S.E.M. of duplicates from three different
experiments. *Pb0.05. Protein knockdown was determined by immunoblot analysis 72 h after transfection. c) MCF-10A cells over-expressing a dominant negative form of FADD
(DN-FADD) or control MCF-10A cells (pBabe) were transfected either with siRNA for FLIPL or scrambled RNA oligonucleotide. After 72 h apoptosis was measured as in Fig. 1. Results
show the average and S.E.M. of duplicates from three different experiments. *Pb0.05. Western blot shows the level of FADD and DN-FADD in control MCF-10A cells and cells over-
expressing DN-FADD. d) MCF-10A cells were transfected with siRNA for FLIPL or Caspase-8, or both of them at the same time. After 72 h apoptosis was determined. Results show the
average and S.E.M. of three different experiments. **Pb0.01. For immunoblot analysis to verify protein knockdown, cells were harvested 72 h after transfection.
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FLIP protein thus allowing spontaneous apoptosis. In contrast, in cells
transfected with FLIPS siRNA, high FLIPL levels remain intact and could
exert their inhibitory action on spontaneous death receptor-mediated
apoptosis.
We have demonstrated that FLIPL knockdown up-regulates TRAIL-
R2 expression and activates caspase-8 in the absence of TRAIL
induction. At present we do not know the molecular mechanism
involved in the control of TRAIL-R2 protein levels by FLIPL. Because
FLIPL could regulate autophagy and protein ubiquitylation [55,56],decreasing FLIPL by siRNA may affect the expression of proteins
required to post-transcriptionally control the cellular levels of TRAIL-
R2. Although ligand-independent activation of death receptors has
been reported when the levels of death receptors are enhanced
through endogenous induction or exogenous over-expression [43,57],
our data show for the ﬁrst time that endogenous TRAIL is required for
the activation of spontaneous apoptosis by FLIPL siRNA. The increased
expression of TRAIL-R2 induced by FLIPL silencing could result in the
formation of a DISC containing endogenous TRAIL, TRAIL-R2, FADD
and procaspase-8 in which caspase-8 is activated. However, we have
Fig. 5. Role of endogenous TRAIL in apoptosis induced by FLIPL silencing in MCF-10A cells. a) MCF-10A cells were transfected with either a siRNA oligonucleotide targeting FLIPL or a
scrambled oligonucleotide for 24 or 48 h. TRAIL levels and FLIPL knockdownwere assessed bywestern blotting. Results are representative of 2 independent experiments. GAPDHwas
used as a protein loading control. b) MCF-10A cells were transfected with either a siRNA oligonucleotide targeting FLIPL or a scrambled oligonucleotide for 24 h and cell surface TRAIL
was assessed by ﬂow cytometry with PE-labelled mouse anti-human TRAIL antibody (―). A PE-labelled mouse IgG1 k isotype control was used for detection of non-speciﬁc binding
(…). As a positive control for the binding of PE-labelled TRAIL antibody to TRAIL, some cultures were incubated for 30 min at 4 °C with TRAIL prior to the incubation with PE-labelled
anti-TRAIL antibody (⁃⁃⁃⁃). Results are representative of 3 independent experiments. c) MCF-10A cells were transfected either with siRNA for FLIPL or scrambled RNA oligonucleotide
(left panel) and incubated for 30 hwith or without a recombinant human TRAIL-R2/Fc chimeric protein (TR2-Fc, 750 ng/ml) to block TRAIL signalling. After this incubation apoptosis
was assessed as described in Material and methods. Other cultures of MCF-10A cells were treated with TRAIL for 24 h in the presence or absence of TRAIL-R2/Fc (150 ng/ml) and
apoptosis was determined as described (right panel). Results show the average and S.E.M. of duplicates from three different experiments. **Pb0.01. d) MCF-10A cells were
transfected with siRNAs for TRAIL for 24 h prior to transfection with siRNA for FLIPL (FL) for 30 h. Apoptosis was measured as described in Fig. 1. Results show the average and range
of triplicates from two different experiments. Immunoblot analysis was performed to verify protein knockdown after FLIPL siRNA transfection.
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exogenous ligand (results not shown), due perhaps to the slow kinetic
of DISC formation and spontaneous cell death in FLIPL knockdown
cells. Our results also indicate that the DISC components co-localize in
amembrane fraction in the absence of exogenous TRAIL. Furthermore,
we have not detected an increased expression of TRAIL and TRAIL-R2
at the cell surface upon FLIPL knockdown. Together, our results
suggest that TRAIL DISC formation and activation of caspase-
8 following FLIPL silencing must take place at an intracellular
membrane compartment in untransformed breast epithelial cells.
Our ﬁndings underscore the complexity of the mechanisms involved
in the spontaneous apoptosis elicited by FLIPL silencing and warrant
further investigation to characterize the intracellular site of caspase-
8 activation.
Development and involution of the mammary gland are proto-
typical examples of the importance of apoptosis in morphogenesisand function of this organ [58]. Thus, the mammary gland provides an
interesting model to characterize the control mechanisms of apopto-
sis in a physiological system that are disrupted during the pathogen-
esis of epithelial tumours [26]. The mammary gland, a glandular
epithelium, is formed by units called acini with a central cavity, the
lumen surrounded by polarized epithelial cells. Apoptosis accom-
panies clearing of the terminal end buds in the developing mammary
gland and lumen formation. Many types of early breast cancer lesions
such as ductal carcinoma in situ are characterized by loss of acinar
organization and ﬁlling of the luminal space [59]. In culture, MCF-10A
cells retainmany characteristics of normal breast epithelium and form
acinar structures when grown in Matrigel. Our results demonstrate
that FLIPL knockdown with lentiviral vectors expressing shRNA
markedly reduces the number of acini in 3D cultures of MCF-10A
cells, which suggests that maintenance of FLIPL levels may have an
important role in the control of morphogenesis in the mammary
Fig. 6. Partial involvement of a mitochondria-operated pathway in apoptosis by FLIPL siRNA. a) MCF-10A cells were transfected either with siRNA for FLIPL or Bid, or both of them at
the same time. After 72 h apoptosis was determined. Results show the average and S.E.M. of three different experiments. *Pb0.05. For immunoblot analysis to verify protein
knockdown, cells were harvested 72 h after transfection. b) MCF-10A cells over-expressing Bcl2 protein or MCF-10A control (pBabe) were transfected either with siRNA for FLIPL or
scrambled RNA oligonucleotide. After 72 h, apoptosis wasmeasured. Results show the average and S.E.M. of three independent experiments. *Pb0.05.Western blot shows Bcl2 levels
in control (pBabe) and Bcl2 cells.
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during morphogenesis of MCF-10A mammary epithelial cells in 3D
basement-membrane cultures and inhibition of TRAIL signalling
during morphogenesis delays lumen formation [28]. Our data in
cells over-expressing FLIP further support the role of this caspaseFig. 7. FLIPL is required for the survival of MCF-10A cells in 3D cultures. MCF-10A cells were
methods. After 48 h cells were harvested for 3Dmorphogenesis assay. Knockdown of FLIPL w
percentage of GFP-positive acini was determined (a,b). At least 100 acini were counted in
(c) MCF-10A cells were transfected for 24 h with siRNA for FLIPL or Caspase-8, or both of the
3D morphogenesis assay. Cells were cultured for 7 days in Matrigel and the number of acininhibitor in regulating lumen formation during morphogenesis in 3D
cultures. Moreover, we have recently described that TRAIL induces
cytoprotective autophagy in monolayer cultures of MCF-10A cells
through the activation of a novel signalling pathway that involves
TAK1, AMPK and mTOR [40]. In these cells, down-regulation of FLIPLinfected with scrambled or FLIPL shRNA lentiviral vectors as described in Material and
as conﬁrmed bywestern blotting. Cells were cultured for 9 days inMatrigel and then the
each experiment. Results show the average and range of two different experiments.
m at the same time as described in Material and methods. Cells were then harvested for
i was determined. Results show the average and range of two different experiments.
Fig. 8. Over-expression of FLIPL delays luminal clearing in MCF-10A morphogenesis assay. MCF-10A cells stably over-expressing either FLIPL or MCF-10A control cells (pBabe) (a)
were used for 3D morphogenesis assay (b). The percentage of acini containing four or less intact nuclei in lumen was measured at the indicated time points during morphogenesis
(c). At least 100 acini were counted in each experiment. Values represent the mean and the SEM of three independent experiments. *Pb0.05.
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motes TRAIL-induced apoptosis (our unpublished observations).
Thus, FLIPL may be playing a central role in the morphogenetic
process by regulating the outcome of TRAIL receptor activation. On the
other hand, it has been recently reported that matrix detachment
induces autophagy in breast epithelial cells and inhibition of
autophagy in MCF-10A enhances anoikis and luminal apoptosis
during morphogenesis [60], further indicating that autophagy plays
a cytoprotective role in these processes. Moreover, the DISC
components FADD and caspase-8 have been involved in matrix
detachment-induced apoptosis in an exogenous ligand-independent
manner [61]. Our unpublished observations demonstrate that FLIP
levels are up-regulated following detachment from the extracellular
matrix and during morphogenesis. Increased FLIP levels in the cell
may presumably prevent epithelial cells from undergoing anoikis
following ECM detachment [62], allowing them to survive provided
that they reattach in a timely manner. Therefore, FLIP levels may be
controlling not only TRAIL-induced apoptosis but also anoikis during
morphogenesis of the mammary gland in cooperation with BH3-only
proteins Bim and Bmf, two essential regulators of morphogenesis
[31,63,64]. On the other hand, activation of spontaneous apoptosis
upon silencing of FLIP has been reported in various tumor cells and
these ﬁndings have led to propose that FLIP could be a potential target
for antitumor therapy [18,38,39]. However, our results imply that
targeting FLIP could also affect viability of normal cells and hence this
therapeutic strategy may not be acceptable.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.10.003.
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